Dr Lal PathLabs

Brokerages expect diagnostic majors to sustain volume growth through FY27, aided by robust demand and stable pricing, though the recent stock rally may cap upside

Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage

Brokerages expect listed diagnostics majors to maintain volume growth through FY27, helped by stable pricing, B2C demand and operating leverage

Geographically, DCB has a diversified pan-India presence with a stronger footprint across western and southern India, while continuing to expand selectively into underpenetrated markets.

Dr Lal PathLabs' share price jumped 8 per cent to a fresh 52-week high of ₹1,893.65 on the BSE today. The company has posted a better-than-expected Q1 show, prompting analysts to raise target prices.

Dr Lal PathLabs' consolidated net profit grew by 21.4 per cent Y-o-Y to ₹170 crore in Q1 of FY27.

Care Ratings expects Dr Lal PathLabs' revenue to grow by 11-12 per cent per annum in the near-to-medium term driven by organic demand growth, its expanding geographical presence and new initiatives.

Metropolis Healthcare share hit a 52-week high of ₹574.45, surging 14 per cent in trade. Thyrocare soared 12 per cent to ₹526.10, while Vijaya Diagnostic Centre gained 7 per cent to ₹1,298.45.

Dr. Lal PathLabs recorded a 16.6 per cent Y-o-Y rise in revenue from operations to ₹702 crore in Q4 FY26 from ₹659.8 crore in the year-ago period

Diagnostics firm reports profit decline due to prior-year tax benefit, while revenue growth remains strong on higher sample volumes and improved test mix

Consolidated net profit fell to 1.31 billion rupees ($13.8 million) in the quarter ended March, from 1.55 billion rupees a year earlier

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions

After a three-year strategic pause, diagnostics firm is unlocking its balance-sheet capacity look for growth-boosting acquisitions

Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion

The ​country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes

The ​country's largest diagnostics firm by revenue took up a one-time charge worth ₹30.1 crore linked to India's new labour codes

Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares

Diagnostic chains are expanding laboratories, integrated centres and collection networks as demand grows for preventive, genomics-led and precision testing across India

Technical charts show Escorts, Hudco, Dr Lal PathLabs, Force Motors and Godrej Consumer were trading above the higher-end of the Bollinger Bands on the daily scale; and can potentially rally up to 23%

Diagnostics chain declares ₹7 per share interim dividend, 1:1 bonus issue